Literature DB >> 22102196

Von Willebrand disease in the United States: a perspective from Wisconsin.

Veronica H Flood1, Joan Cox Gill, Kenneth D Friedman, Daniel B Bellissimo, Sandra L Haberichter, Robert R Montgomery.   

Abstract

Von Willebrand disease (VWD) is a common bleeding disorder with prevalence in the United States of 0.01 to 1% and a prevalence in the region around Milwaukee, Wisconsin, of at least 0.025%. Care of local patients with VWD primarily occurs through our comprehensive treatment centers, although some patients are managed solely by their primary care physician or community hematologist. Type 1 VWD is the most common subtype, with more females carrying this diagnosis than males. Diagnosis and treatment in general follows guidelines outlined by the National Institutes of Health. An ongoing study, the Zimmerman Program for the Molecular and Clinical Biology of VWD, is currently enrolling patients with all VWD subtypes across the United States to better delineate the extent of VWD and correlate bleeding symptoms with laboratory findings and VWF ( Von Willebrand factor) sequence variations. Results so far have shown that VWF gene polymorphisms are common, particularly in African Americans, and may affect laboratory assays of VWF function. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22102196      PMCID: PMC3807766          DOI: 10.1055/s-0031-1281039

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  27 in total

Review 1.  Impact, diagnosis and treatment of von Willebrand disease.

Authors:  J E Sadler; P M Mannucci; E Berntorp; N Bochkov; V Boulyjenkov; D Ginsburg; D Meyer; I Peake; F Rodeghiero; A Srivastava
Journal:  Thromb Haemost       Date:  2000-08       Impact factor: 5.249

2.  DDAVP for von Willebrand menorrhagia--severe hyponatraemia, haemolysis, seizure, coma.!! Caution.

Authors:  O Olowokure; M Fishman; C Cromwell; L Aledort
Journal:  Haemophilia       Date:  2009-05       Impact factor: 4.287

3.  Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.

Authors:  Augusto B Federici; Pier M Mannucci; Giancarlo Castaman; Luciano Baronciani; Paolo Bucciarelli; Maria T Canciani; Alessandro Pecci; Peter J Lenting; Philip G De Groot
Journal:  Blood       Date:  2008-09-19       Impact factor: 22.113

4.  Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD.

Authors:  V H Flood; C A Lederman; J S Wren; P A Christopherson; K D Friedman; R G Hoffmann; R R Montgomery
Journal:  J Thromb Haemost       Date:  2010-03-23       Impact factor: 5.824

5.  Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.

Authors:  Veronica H Flood; Joan Cox Gill; Patricia A Morateck; Pamela A Christopherson; Kenneth D Friedman; Sandra L Haberichter; Brian R Branchford; Raymond G Hoffmann; Thomas C Abshire; Jorge A Di Paola; W Keith Hoots; Cindy Leissinger; Jeanne M Lusher; Margaret V Ragni; Amy D Shapiro; Robert R Montgomery
Journal:  Blood       Date:  2010-03-15       Impact factor: 22.113

6.  Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease.

Authors:  Lee A O'Brien; Paula D James; Maha Othman; Ergul Berber; Cherie Cameron; Colleen R P Notley; Carol A Hegadorn; Jeffrey J Sutherland; Christine Hough; Georges E Rivard; Denise O'Shaunessey; David Lillicrap
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

Review 7.  Perioperative crystalloid and colloid fluid management in children: where are we and how did we get here?

Authors:  Ann G Bailey; Peggy P McNaull; Edmund Jooste; Jay B Tuchman
Journal:  Anesth Analg       Date:  2009-12-02       Impact factor: 5.108

8.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Authors:  Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

Review 9.  Von Willebrand disease: key points from the 2008 National Heart, Lung, and Blood Institute guidelines.

Authors:  Andra H James; Marilyn J Manco-Johnson; Barbara P Yawn; Jennifer E Dietrich; William L Nichols
Journal:  Obstet Gynecol       Date:  2009-09       Impact factor: 7.661

10.  Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor.

Authors:  Anne F Riddell; Keith Gomez; Carolyn M Millar; Gillian Mellars; Saher Gill; Simon A Brown; Megan Sutherland; Mike A Laffan; Thomas A J McKinnon
Journal:  Blood       Date:  2009-08-17       Impact factor: 22.113

View more
  6 in total

Review 1.  Diagnostic approach to von Willebrand disease.

Authors:  Christopher Ng; David G Motto; Jorge Di Paola
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

2.  A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.

Authors:  Agnès Veyradier; Pierre Boisseau; Edith Fressinaud; Claudine Caron; Catherine Ternisien; Mathilde Giraud; Christophe Zawadzki; Marc Trossaert; Nathalie Itzhar-Baïkian; Marie Dreyfus; Roseline d'Oiron; Annie Borel-Derlon; Sophie Susen; Stéphane Bezieau; Cécile V Denis; Jenny Goudemand
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

3.  Recombinant von Willebrand factor for severe gastrointestinal bleeding unresponsive to other treatments in a patient with type 2A von Willebrand disease: a case report.

Authors:  Racquel Brown
Journal:  Blood Coagul Fibrinolysis       Date:  2017-10       Impact factor: 1.276

4.  Closing the gap - detection of clinically relevant von Willebrand disease in emergency settings through an improved algorithm based on rotational Thromboelastometry.

Authors:  H-G Topf; E R Strasser; G Breuer; W Rascher; M Rauh; F B Fahlbusch
Journal:  BMC Anesthesiol       Date:  2019-01-10       Impact factor: 2.217

5.  Phenotypic and Genotypic Characterization of von Willebrand Factor Gene (Exon 18 and 20) in Saudi Healthy Individuals.

Authors:  Faisal M Alzahrani; Nemat Aldossary; Fathelrahman Mahdi Hassan
Journal:  Med Arch       Date:  2020-10

6.  Economic Burden Associated with Major Surgery in Patients with von Willebrand Disease: A United States Retrospective Administrative Database Analysis.

Authors:  Abiola Oladapo; Yanyu Wu; Mei Lu; Sepehr Farahbakhshian; Bruce Ewenstein
Journal:  J Blood Med       Date:  2021-08-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.